BioArctic, Eisai Win US Approval for Leqembi Iqlik as Starting Dose of Early Alzheimer's Treatment

12:03 AM EDT, 07/14/2026 (MT Newswires) -- BioArctic (BIOA-B.ST) said its partner Eisai secured the US Food and Drug Administration's approval for Leqembi Iqlik subcutaneous injection as a once-weekly starting dose for the treatment of early Alzheimer's disease. The positive regulatory decision is based on a comprehensive clinical data package comprising multiple studies that showed the once-weekly subcutaneous injection worked as well as intravenous dosing, according to a Monday release. The approved initiation dose is 500 milligrams once weekly, delivered via two 250-milligram injections. Leqembi Iqlik, or lecanemab irmb, is expected to be launched in the US in late August.